These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 18804815

  • 1. Atorvastatin inhibits renal crystal retention in a rat stone forming model.
    Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A.
    J Urol; 2008 Nov; 180(5):2212-7. PubMed ID: 18804815
    [Abstract] [Full Text] [Related]

  • 2. Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis.
    Itoh Y, Yasui T, Okada A, Tozawa K, Hayashi Y, Kohri K.
    J Urol; 2005 Jan; 173(1):271-5. PubMed ID: 15592095
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone, a peroxisome proliferator activated receptor γ agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats.
    Taguchi K, Okada A, Yasui T, Kobayashi T, Ando R, Tozawa K, Kohri K.
    J Urol; 2012 Sep; 188(3):1002-11. PubMed ID: 22819112
    [Abstract] [Full Text] [Related]

  • 4. Hepatocyte growth factor has protective effects on crystal-cell interaction and crystal deposits.
    Tei N, Tsujihata M, Tsujikawa K, Yoshimura K, Nonomura N, Okuyama A.
    Urology; 2006 Apr; 67(4):864-9. PubMed ID: 16600342
    [Abstract] [Full Text] [Related]

  • 5. Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin.
    Park HK, Jeong BC, Sung MK, Park MY, Choi EY, Kim BS, Kim HH, Kim JI.
    J Urol; 2008 Apr; 179(4):1620-6. PubMed ID: 18295251
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status.
    Thamilselvan S, Menon M.
    BJU Int; 2005 Jul; 96(1):117-26. PubMed ID: 15963133
    [Abstract] [Full Text] [Related]

  • 14. Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria.
    Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F.
    J Urol; 2001 Jul; 166(1):275-80. PubMed ID: 11435885
    [Abstract] [Full Text] [Related]

  • 15. Renal oxidative vulnerability due to changes in mitochondrial-glutathione and energy homeostasis in a rat model of calcium oxalate urolithiasis.
    Meimaridou E, Lobos E, Hothersall JS.
    Am J Physiol Renal Physiol; 2006 Oct; 291(4):F731-40. PubMed ID: 16670437
    [Abstract] [Full Text] [Related]

  • 16. The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis.
    Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H.
    J Urol; 2001 Sep; 166(3):1078-82. PubMed ID: 11490302
    [Abstract] [Full Text] [Related]

  • 17. Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats.
    Moriyama MT, Glenton PA, Khan SR.
    J Urol; 2001 May; 165(5):1687-92. PubMed ID: 11342956
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.